The API Patent Cliff 2026–2029: Which Molecules Have Suppliers Ready
Patent expiry lists are everywhere. What they almost never show is whether anyone actually makes the ingredient. We took 90 active pharmaceutical ingredients whose US patents expire within three years and joined each one to the number of API suppliers on record. A third have fewer than three. Sixteen have none at all.
Data as of August 2026 · Sources: FDA Orange Book, FDA Drug Master Files, EU & UK GMP registers · Analysis by PharmaTek Intelligence
Key findings
Patent expiry is not the same as a generic opportunity
16 of the 90 molecules coming off patent have no API supplier on record at all, and a further 17 have only one or two. For those, the binding constraint is not intellectual property — it is that somebody has to build and qualify a supply chain first, which typically takes longer than the patent has left to run.
The crowded end is very crowded
At the other extreme, 32 molecules already have ten or more API suppliers, led by pregabalin with 39 suppliers across 407 approved products. Where supply is this deep, the launch race is decided on price, capacity and qualification speed — not on securing material at all.
Two-thirds have at least one GMP-certified supplier
63 of the 90 have at least one supplier holding a current GMP certificate in the EU or UK registers. The remaining 27 may still have capable suppliers — but their GMP standing is not evidenced in the public European record, which is a due-diligence gap rather than a disqualification.
Supplier readiness across the cliff
The 90 APIs expiring by 2029, grouped by how many API suppliers are on record. Average across the group: 8.1 suppliers.
Red and amber together account for 33 of 90 molecules.
Deep supply — the contested launches
Ten or more API suppliers already on record.
No API supplier on record
Approved products exist; public API supply does not.
What this means for generics planning
A patent expiry date tells you when you are legally free to launch. It says nothing about whether you can obtain the ingredient, and the two questions have very different lead times. Qualifying a new API supplier — audit, samples, stability, regulatory filing — routinely takes eighteen months to three years. For the 33 molecules on this list with fewer than three suppliers, that clock is already running.
The practical read is to sort the cliff into three buckets. Where supply is deep, your risk is margin compression, and the work is commercial. Where supply is thin, your risk is not getting material at all, and the work is starting supplier development now. Where there is no supplier on record, the opportunity is real but it is a development project, not a procurement one — and the first company to qualify a source has a structural head start that the patent date never revealed.
Supplier count is also a proxy for switching risk after launch. A molecule with a single API source is a single point of failure regardless of how attractive the market looks, and it is worth weighing that against the DMF and GMP standing of whoever does make it.
PharmaTek tracks patent and exclusivity dates alongside live supplier counts, GMP certificates and inspection history for each substance, so this analysis is a starting point rather than a one-off snapshot. Search any molecule in the supplier directory.
Methodology & sources
- Patent and exclusivity dates come from the FDA Orange Book. We hold dated patent information for 688 substances; 90 have a latest-patent expiry between August 2026 and August 2029, and 153 within five years.
- “Suppliers” counts distinct API suppliers on record for the substance, derived from US Drug Master File holders and EU Certificates of Suitability. It measures publicly evidencedsupply: a manufacturer serving only non-US, non-EU markets, or supplying without a DMF, will not appear. Zero therefore means “none on public record”, not “none in existence”.
- Where a substance carries several patents we use the latest expiry, which is the date that actually gates entry. Exclusivity periods can extend protection beyond patent expiry and are tracked separately; this analysis is organised by patent date.
- GMP coverage is matched against the EU (EudraGMDP) and UK (MHRA-GMDP) certificate registers by site name, a conservative match — so 63 is a floor.
- This is a supply-availability analysis, not legal advice. Patent status varies by jurisdiction and by formulation, and freedom to operate should be confirmed with counsel.
Cite this report: PharmaTek Intelligence, “The API Patent Cliff 2026–2029: Which Molecules Have Suppliers Ready,” August 2026. https://pharmatek.co.uk/reports/api-patent-cliff
See who supplies any molecule on this list
Patent dates, API suppliers, GMP certificates and inspection history for thousands of substances — in one place.
Explore the directory